Drug Type Recombinant protein |
Synonyms Isunakinra (USAN/INN), EBI 005 1, EBI 005 2 + [4] |
Target |
Action inhibitors |
Mechanism IL-1α inhibitors(Interleukin-1 alpha inhibitors), IL-1β inhibitors(Interleukin-1 beta inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Conjunctivitis, Allergic | Phase 3 | United States | 01 Jul 2015 | |
Dry Eye Syndromes | Phase 3 | United States | 01 Jan 2014 | |
Metastatic Colorectal Carcinoma | Phase 2 | United States | 30 Jan 2025 | |
Solid tumor | Phase 2 | Sweden | 15 Jul 2022 | |
Locally Advanced Malignant Solid Neoplasm | Phase 2 | United States | 01 Sep 2020 |
Not Applicable | 15 | jkiiqravck(ezckfrvtrk) = zccjnzqekc ljqufowizg (exabpsxtlk ) | - | 07 Dec 2023 | |||
jkiiqravck(ezckfrvtrk) = hjvcvwtpon ljqufowizg (exabpsxtlk ) | |||||||
Phase 1 | 15 | bteoqwtibn(vsphypnhvq) = suyrhxwctj mibemwxukp (qvwqyxsbjo ) View more | Positive | 26 May 2023 | |||
Phase 1 | - | lvdarnqdvs(trmatjsuvw) = aagzlhdnnw cbbbufmala (gqqeiyjugw ) View more | Positive | 01 Sep 2017 | |||
Placebo | - | ||||||
Phase 3 | - | EBI-005 5 mg/mL | abuqhzxfec(uyxasutgwm) = dmonshdnok tnxdobbeci (dklikszvem ) View more | Positive | 01 Jun 2015 | ||
EBI-005 20 mg/mL | abuqhzxfec(uyxasutgwm) = gdkvyoasdw tnxdobbeci (dklikszvem ) View more | ||||||
Phase 3 | 669 | ogzfkgzwwq(fkhgdtzusb) = xitzekrznv yxkzpxyjqj (rdoaearwln ) View more | Negative | 18 May 2015 | |||
Placebo | - | ||||||
Not Applicable | 74 | EBI-005 5 mg/mL | eacwujfxhl(ridcfrwlsw) = iamnjlfkcb kurrwqbbbh (qpbwnisjxu ) | - | 01 Apr 2014 | ||
EBI-005 20 mg/mL | eacwujfxhl(ridcfrwlsw) = htecdhnvmu kurrwqbbbh (qpbwnisjxu ) |